Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
Genomics Institute of the Novartis Research Foundation · Harvard University · +1 more institution
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
869
total citations
- FWCI
- 62.98
- Percentile
- 100%
- References
- 31
Citations per year
Authors
25- YJYong JiaCorresponding
Genomics Institute of the Novartis Research Foundation
- CYCai‐Hong Yun
Harvard University, Dana-Farber Cancer Institute
- EPEunyoung Park
Dana-Farber Cancer Institute, Harvard University
- DEDalia Ercan
Dana-Farber Cancer Institute
- MMMari Manuia
Genomics Institute of the Novartis Research Foundation
Topics & keywords
Topics
Keywords
- T790M
- Allosteric regulation
- Afatinib
- Erlotinib
- Epidermal growth factor receptor
- Gefitinib
- EGFR inhibitors
- Cetuximab
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.